Daily liraglutide injections achieve 5–10% average weight loss over one year (SCALE trial).
Weekly semaglutide injections (up to 2.4mg) are more convenient and typically lead to 10–15% reductions (STEP trials).
Large clinical trials provide clear evidence of effectiveness:
- The STEP trials on weekly high-dose semaglutide (up to 2.4mg) showed average weight reductions of 10–15% of body weight over 68 weeks.
- The SURMOUNT-1 trial on tirzepatide demonstrated even greater outcomes, with patients losing 15–20% of body weight at higher doses.
- The PIONEER trials on oral semaglutide tablets showed average reductions of 4–6 kg over six months.
- The SCALE trial on daily liraglutide injections showed weight reductions of 5–10% over one year.
These results highlight that injectables generally deliver the greatest effect, while oral tablets and daily injections provide moderate but still meaningful reductions.